SERB signs agreement to acquire Idefirix rights for $133.6m

SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix from Hansa Biopharma for a total of $133.6m. Hansa will receive €110m upfront and a further €5m once the European Medicines Agency accepts Idefirix’s full approval filing. Idefirix desensitises adult kidney transplant patients with reactive IgG antibodies that could target donated tissues and increase rejection. Credit: sasirin pamai / Shutterstock.com. SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix (imlifidase) from Hansa Biopharma for a total of €115m ($133.6m). The deal covers the European Union, Iceland, Liechtenstein, Norway, Switzerland,…

Source: Pharmaceutical Technology